(Q34090789)

30 July 2017

1 reference

title

Update on gout: new therapeutic strategies and options (English)

1 reference

30 July 2017

Robert Terkeltaub

1

1 reference

PubMed ID

20046204

30 July 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

Nature Reviews Rheumatology

30 July 2017

1 reference

30 July 2017

6

1 reference

30 July 2017

1

1 reference

30 July 2017

30-38

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2009.236

30 July 2017

0 references

cites work

Clinical manifestations of hyperuricemia and gout.

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Uric acid nephrolithiasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

31 March 2020

Gout and hyperuricemia

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Mechanisms of inflammation in gout

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Dual energy computed tomography in tophaceous gout

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Uric acid and cardiovascular risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Gout: on the brink of novel therapeutic options for an ancient disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Uricase and other novel agents for the management of patients with treatment-failure gout

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Urate transport across the apical membrane of renal proximal tubules

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Sodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with gout.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Sex-specific association of the putative fructose transporter SLC2A9 variants with uric acid levels is modified by BMI

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

The inflammatory process of gout and its treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Gout-associated uric acid crystals activate the NALP3 inflammasome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

31 March 2020

Clinical practice. Gout

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Comparison of drug adherence rates among patients with seven different medical conditions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Adherence with urate-lowering therapies for the treatment of gout

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

31 March 2020

Colchicine update: 2008.

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Melanocortin 3 receptors control crystal-induced inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

A pilot study of IL-1 inhibition by anakinra in acute gout

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Treatment-failure gout: a moving target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Gout medication treatment patterns and adherence to standards of care from a managed care perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Quality of life and disability in patients with treatment-failure gout.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Gout. Novel therapies for treatment of gout and hyperuricemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Quality of life and quality of care for patients with gout

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Long-term cardiovascular mortality among middle-aged men with gout

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Adherence to treatment guidelines in two primary care populations with gout

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.236

Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis

31 March 2020

1 reference

12 December 2020

Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout

1 reference

12 December 2020

Learning how and when to employ uricase as bridge therapy in refractory gout.

1 reference

12 December 2020

1 reference

12 December 2020

Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study.

1 reference

12 December 2020

Quality of care in gout: from measurement to improvement.

1 reference

12 December 2020

Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2009.236

1 reference

PubMed ID

20046204

Dimensions Publication ID

30 July 2017

0 references

1 reference

PubMed ID

20046204